ABSTRACT

**Background:** Glutamate is the main excitatory neurotransmitter. Excessive glutamate causes excitatory toxicity and increases intracellular calcium, leading to neuronal death. Parvalbumin is a calcium-binding protein that regulates calcium homeostasis. Quercetin is a polyphenol found in plant and has neuroprotective effects against neurodegenerative diseases.

**Objectives:** We investigated whether quercetin regulates apoptosis by modulating parvalbumin expression in glutamate induced neuronal damage.

**Methods:** Glutamate was treated in hippocampal-derived cell line, and quercetin or vehicle was treated 1 h before glutamate exposure. Cells were collected for experimental procedure 24 h after glutamate treatment and intracellular calcium concentration and parvalbumin expression were examined. Parvalbumin small interfering RNA (siRNA) transfection was performed to detect the relation between parvalbumin and apoptosis.

**Results:** Glutamate reduced cell viability and increased intracellular calcium concentration, while quercetin preserved calcium concentration and neuronal damage. Moreover, glutamate reduced parvalbumin expression and quercetin alleviated this reduction. Glutamate increased caspase-3 expression, and quercetin attenuated this increase in both parvalbumin siRNA transfected and non-transfected cells. The alleviative effect of quercetin was statistically significant in non-transfected cells. Moreover, glutamate decreased bcl-2 and increased bax expressions, while quercetin alleviated these changes. The alleviative effect of quercetin in bcl-2 family protein expression was more remarkable in non-transfected cells.

**Conclusions:** These results demonstrate that parvalbumin contributes to the maintainance of intracellular calcium concentration and the prevention of apoptosis, and quercetin modulates parvalbumin expression in glutamate-exposed cells. Thus, these findings suggest that quercetin performs neuroprotective function against glutamate toxicity by regulating parvalbumin expression.

**Keywords:** Neuroprotection; parvalbumin; quercetin

INTRODUCTION

Glutamate is a major excitatory neurotransmitter that abundantly presents in the central nervous system [1]. It is involved in neuroplasticity, learning, and memory function in the
brain [2,3]. However, excessive glutamate causes excitability toxicity and leads to nerve damage. Therefore, the regulation of proper glutamate concentration is required to perform normal brain function [4]. Glutamate excitatory toxicity is associated with N-methyl-D-aspartate receptors, which induce neuronal calcium influx, reactive oxygen species (ROS) generation, and apoptosis [5-7]. It induces various neurodegenerative diseases such as stroke, Alzheimer’s disease, and Parkinson’s disease [8,9]. It also increases the intracellular calcium concentration, which finally causes cell damage [10,11].

Excessive intracellular calcium triggers oxidative stress, lipid peroxidation, mitochondrial depolarization, and neurodegeneration [12]. Moreover, it activates the caspase cascade signaling pathway and causes apoptotic cell death [13]. Parvalbumin is a calcium-binding protein that widely distributed in various areas of the brain. It plays an important role in maintaining intracellular calcium concentration [14]. Parvalbumin protects the mitochondria from calcium overload by inhibiting a depolarization-induced calcium increase and buffering calcium in an intracellular environment [15]. It modulates synaptic plasticity and regulates neuronal excitability by controlling the electrical properties of neurons [16]. Down-regulation of parvalbumin expression induces ROS formation and nerve damage [17]. Based on previous studies, the down-regulation of calcium-regulating proteins is closely linked to neuronal damage.

Quercetin is a polyphenolic substance that can be easily found in various fruits and vegetables [18]. It acts as a potent antioxidant and exerts beneficial effects on cancer, diabetes, and cardiovascular disease [19-21]. It has neuroprotective effects in various neurodegenerative diseases, including traumatic brain injury and stroke [22,23]. It also protects neurons against glutamate toxicity [24]. Moreover, quercetin exerts neuroprotective effects on styrene oxide-induced neuronal cell death by reducing ROS and controlling calcium concentrations [25]. We have previously shown that quercetin exerts neuroprotective effects by regulating the calcium sensor protein hippocalcin in stroke animal model [26]. Quercetin also alleviates the increase in calcium concentration in neuronal damage caused by glutamate toxicity [26]. We have previously reported that quercetin attenuates the reduction of parvalbumin in stroke animal models [27]. However, the exact molecular biological mechanism for the neuroprotective effect of quercetin against glutamate toxicity has not been fully elucidated. We propose that quercetin regulates calcium-binding protein and protects neurons against glutamate toxicity. Thus, we investigated whether quercetin regulates intracellular calcium concentration and apoptosis-related protein expression through the modulation of parvalbumin expression in glutamate-induced neuronal damage.

**MATERIALS AND METHODS**

**Hippocampal cell line culture**

Hippocampal cell line (HT22) was cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL, USA) that contains heat-inactivated 10% fetal bovine serum (FBS) and antibiotics (100 units/mL of penicillin and 100 μg/mL of streptomycin). HT22 cells were cultured in a humid incubator at 37°C in 5% CO₂ and culture media was replaced to maintain proper nutritional environment. Quercetin (Sigma-Aldrich, USA) was dissolved in phosphate buffer saline (PBS) and PBS was used for vehicle solution. Quercetin (1, 3, and 5 μM) or PBS was supplemented into culture media 1 h before glutamate (5 mM, Sigma-Aldrich) treatment [26]. Cells were collected 24 h after glutamate treatment for further experimental procedure.
**Cell viability test**

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was carried out to measure cell viability. HT22 cells were seeded at $5 \times 10^3$ cells/well density in 96-well culture plate and incubated for 24 h. Glutamate and/or quercetin were treated as previous described dose. MTT solution (5 mg/mL) was added to each well and incubated for 4 h at 37°C in light blocked place. MTT formazan crystals were dissolved into dimethyl sulfoxide and absorbance of 570 nm was measured. Cell viability was measured by the ratio of absorbance value (%) and determined as a percentage of the absorbance of each group to that of PBS group.

**Intracellular calcium concentration measurement**

Fluo-3-acetoxymethyl (Fluo-3 AM, Thermo Fisher Scientific, USA) was applied to measure the concentration of intracellular calcium as a previously described [28]. HT22 cells were incubated in DMEM containing Fluo-3 AM (3 μM) for 1 h at 37°C and trypsinized by 0.05% trypsin solution. Detached cells were centrifuged at 1,000 g for 10 min and re-suspended in Locke’s solution (pH 7.3, 130 mM NaCl, 15 mM glucose, 10 mM HEPES, 5 mM KCl, 2.2 mM CaCl$_2$, and 2 mM MgCl$_2$) at a proper cell density (approximately $1 \times 10^6$ cells/mL). Cells were subjected to fluorescence-activated cell sorting (FACS) and intensity of Fluo-3 AM fluorescence was measured by FACSVerse flow cytometer (BD Bioscience, USA). Fluo-3 AM in Locke’s solution was excited at 488 nm and measured at 530 ± 20 nm. Measured fluorescence intensity was analyzed by FACSuite software (BD Bioscience). Intracellular calcium concentration was calculated according to a previously described formula $[\text{Ca}^{2+}]_i = K_d \times (F - F_{\text{min}})/(F_{\text{max}} - F)$ [29]. Ca$^{2+}$ dissociation constant of Fluo-3 AM is expressed as $K_d$ and is approximately 400 nM at vertebrate ionic strength. $F$ indicates the mean fluorescence intensity of total cell sample at 530 ± 20 nm. $F_{\text{max}}$ means the maximal fluorescence intensity of Fluo-3 AM saturated with Ca$^{2+}$ by ionomycin. $F_{\text{min}}$ means the minimal fluorescence intensity of Ca$^{2+}$-free environment made by ethylene glycol tetra acetic acid.

**Parvalbumin small interfering RNA (siRNA) transfection**

Parvalbumin siRNA transfection was performed according to the manufacturer’s instructions. HT22 cells were cultured in DMEM medium and culture medium was changed to DMEM medium without FBS and antibiotics 24 h before transfection. Liposome solution (DMEM containing Lipofectamine 3000, Thermo Fisher Scientific) was mixed with parvalbumin siRNA (Thermo Fisher Scientific) and incubated for 20 min. Mixture was added to culture medium and medium was changed 48 h after transfection. Quercetin (5 μM) or PBS was treated to transfected cells 1 h before glutamate (5 mM) treatment, and transfected cells were collected 24 h after glutamate treatment.

**Western blot analysis**

Collected cells were lysed in lysis buffer (1% Triton X-100, 1 mM EDTA in PBS [pH 7.4]) contained phenylmethanesulfonyl fluoride (Sigma-Aldrich) and sonicated. Sonicated lysates were centrifuge at 15,000 g for 1 h at 4°C and supernatants were collected. Concentration of proteins was analyzed using bicinchoninic acid protein assay kit (Pierce, USA). Proteins (30 μg) were electrophoresed in 10% sodium dodecyl sulfate polyacrylamide gels at 10 mA for 30 min and consecutively run at 20 mA for 90 min. Loaded gels were transferred to polyvinyl difluoride membrane (Sigma-Aldrich) at 120 V for 2 h. Transferred membranes were incubated with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h to block non-specific reaction and washed with TBST for 10 min. Washed membranes were reacted with anti-parvalbumin (diluted 1:1,000, Thermo Fisher Scientific), anti-caspase-3, anti-cleaved caspase-3, anti-bcl-2, anti-bax (diluted 1:1,000, Cell Signaling Technology,
USA), and anti-β-actin (diluted 1:1,000, Santa Cruz Biotechnology, USA) for overnight at 4°C. They were washed with TBST and incubated with horseradish peroxide-conjugated anti-rabbit IgG or anti-mouse IgG (diluted 1:5,000, Cell Signaling Technology) for 2 h at room temperature. Membranes were washed with TBST for 10 min and reacted with enhanced chemiluminescence reagents (GE Healthcare, UK). They were exposed on X-ray film (FujiFilm Co., Japan) and developed with developer solution until protein bands were visualized. They were continuously washed with water, fixed with fixation solution, washed with water, and dried. The intensity of band was statically analyzed by Image J software. They were expressed as a ratio of specific protein band intensity to β-actin band intensity

**Immunocytochemistry**
Cells were cultured on gelatin-coated glass slide, fixed with 4% natural buffered paraformaldehyde solution (pH 7.4), and washed with PBS for 10 min. They were reacted with normal goat serum for 1 h at room temperature to block non-specific binding and incubated with anti-parvalbumin polyclonal antibody (1:100, Thermo Fisher Scientific) for overnight at 4°C. Cells were washed with PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit secondary antibody for 2 h at room temperature. They were stained with 4,6-diamino-2-phenylindole dihydrochloride (DAPI) as a counter staining, mounted with fluorescent mounting medium (Dako, North America Inc., USA), and observed with confocal fluorescence microscope (FV-1000, Olympus, Japan)

**Statistical analysis**
Data were presented as means ± SD. Results of each groups were compared by two-way analysis of variance (ANOVA) followed by post-hoc Scheffe’s test and the effect of quercetin by dose-dependent manner were compared by two-way ANOVA followed by Dunnett’s multiple comparison. \( p < 0.05 \) was considered to be statistically significant.

**RESULTS**
We confirmed the neuroprotective effect of quercetin in glutamate-exposed neurons. Figure 1A presented representative photos of neurons in glutamate and/or quercetin-treated groups. Glutamate toxicity significantly reduced cell viability, whereas quercetin administration prevented this reduction. The protective effects of quercetin were dose-dependent. Cell viability values were 17.7 ± 5.3 in the glutamate-only treated cells and 28.0 ± 8.6, 64.3 ± 4.3, and 82.0 ± 3.2 in the quercetin (1, 3, and 5 μM) and glutamate co-treated cells, respectively (Fig. 1B). Intracellular calcium levels were significantly elevated in the glutamate-only treated cells, while quercetin administration attenuated this rise (Fig. 1C). Quercetin regulated intracellular calcium levels in a dose-dependent manner. The intracellular calcium concentration was 740 nM in the glutamate-only treated cells and 433, 231, and 167 in the the quercetin (1, 3, and 5 μM) and glutamate co-treated cells, respectively (Fig. 1D).

Parvalbumin expression was decreased in the glutamate-only treated cells, while quercetin prevented this decrease (Fig. 2). Immunocytochemical staining revealed that the number of parvalbumin-positive cells was remarkably reduced in the glutamate-only treated cells, but quercetin pretreatment alleviated this decrease in a dose-dependent manner (Fig. 2A and B). Parvalbumin was strongly expressed in the cytoplasm of neurons. In results of Western blot analysis, parvalbumin protein levels were 0.18 ± 0.03 in the glutamate-only treated cells and
Quercetin regulates parvalbumin expression

0.22 ± 0.03, 0.75 ± 0.04, and 0.80 ± 0.03 in the quercetin (1, 3, and 5 μM) and glutamate co-treated cells, respectively (Fig. 2C and D).

Fig. 3 showed parvalbumin and caspase-3 expression levels in glutamate- and/or quercetin (Que)-treated hippocampal neuronal cells (HT22). HT22 cells were treated with glutamate (5 mM) for 24 h and quercetin (1, 3, and 5 μM) was treated 1 h before glutamate exposure. Cell viability was assessed with the MTT assay (B). Cell survival was expressed as a percentage of PBS-treated cells. Neurons were labeled with Fluo-3 AM were measured using a luminescence spectrophotometer (D). Data (n = 5) are presented as means ± SEM.

*p < 0.05, **p < 0.001.
**Quercetin regulates parvalbumin expression**

**Fig. 2.** Representative images of double immunofluorescence labeling (A and B) with parvalbumin (green color) and DAPI (nuclei marker, blue) taken at a magnification of 200x. Western blot analysis (C and D) of parvalbumin in glutamate (Glu)- and/or quercetin (Que)-treated hippocampal neuronal cells. Glutamate (5 mM) was administered for 24 h and quercetin (1, 3, and 5 μM) was treated 1 h before glutamate exposure. Magnified photo is an enlarged image of square area (400×). Parvalbumin-positive cells expression was calculated the percentage of the number of parvalbumin-positive cells to the number of DAPI-positive cells (B). Densitometric analysis results are presented as the ratio of parvalbumin intensity to β-actin intensity (D). Data (n = 5) are presented as means ± SEM. *p < 0.05, **p < 0.001.
treatment increased caspase-3 and cleaved caspase-3 expressions regardless of the siRNA transfection, while quercetin attenuated the glutamate-induced these increases. Caspase-3 and cleaved caspase-3 expressions were greater in parvalbumin siRNA-transfected cells than in non-transfected cells (Fig. 3B). Caspase-3 levels in parvalbumin siRNA-transfected cells were 0.98 ± 0.03 in exposed to glutamate and 0.60 ± 0.05 in subjected to quercetin and glutamate (Fig. 3D). Cleaved caspase-3 levels in siRNA-transfected cells were 0.89 ± 0.03 in the glutamate-treated cells and 0.75 ± 0.03 in the quercetin and glutamate co-treated cells (Fig. 3E).

We evaluated the expression levels of bcl-2 and bax proteins in glutamate-treated cells with parvalbumin siRNA transfection. Glutamate treatment significantly reduced the expression of bcl-2, but quercetin treatment alleviated this reduction. Bcl-2 expression levels in parvalbumin siRNA-transfected cells were lower than in non-transfected cells (Fig. 4A). Bcl-2 expression levels in siRNA-transfected cells were 0.06 ± 0.01 in the glutamate-only treated

![Western blot analysis of parvalbumin (A and C), caspase-3 (B and D), and cleaved caspase-3 (B and E) in glutamate (Glu)- and/or quercetin (Que)-treated hippocampal neuronal cells with or without parvalbumin siRNA transfection. Glutamate (5 mM) was exposed for 24 h and quercetin (3 μM) was treated 1 h before glutamate exposure. Data are presented as the ratio of detected protein intensity to β-actin intensity. Data (n = 5) are presented as means ± SEM. *p < 0.05 in non-transfected cells, †p < 0.05 in siRNA transfected cells.

Fig. 3. Western blot analysis of parvalbumin (A and C), caspase-3 (B and D), and cleaved caspase-3 (B and E) in glutamate (Glu)- and/or quercetin (Que)-treated hippocampal neuronal cells with or without parvalbumin siRNA transfection. Glutamate (5 mM) was exposed for 24 h and quercetin (3 μM) was treated 1 h before glutamate exposure. Data are presented as the ratio of detected protein intensity to β-actin intensity. Data (n = 5) are presented as means ± SEM. *p < 0.05 in non-transfected cells, †p < 0.05 in siRNA transfected cells.
In contrast to bcl-2 expression, bax expression was increased in the glutamate-only treated cells, but quercetin co-treatment attenuated this increase. Bax expression levels in the parvalbumin siRNA-transfected cells were higher than in the non-transfected cells (Fig. 4B). They were 0.60 ± 0.03 in the glutamate-only treated cells and 0.51 ± 0.06 in the quercetin and glutamate co-treated cells (Fig. 4D). Moreover, the ratio of bcl-2 to bax decreases in glutamate-only treated cells, quercetin treatment prevented this decrease. These levels were lower in siRNA-transfected cells than in non-transfected cells. They were 0.10 ± 0.01 in the glutamate-only treated cells and 0.20 ± 0.02 in the quercetin and glutamate co-treated cells with siRNA transfection (Fig. 4E).

Fig. 4. Western blot analysis of bcl-2 (A and C), bax (B and D), and bcl to bax ratio (E) in glutamate (Glu)- and/or quercetin (Que)-treated HT22 cells with or without parvalbumin siRNA transfection. Glutamate (5 mM) was exposed for 24 h and quercetin (3 μM) was treated 1 h before glutamate exposure. Data are presented as the ratio of bcl-2 or bax intensity to β-actin intensity. Data (n = 5) are presented as means ± SEM. *p < 0.05 in non-transfected cells, †p < 0.05 in siRNA transfected cells.
DISCUSSION

Glutamate toxicity causes morphological changes such as dendritic atrophy and neuronal body contraction, induces neuronal cell death, and eventually reduces cell viability [30]. We confirmed that quercetin exerts a neuroprotective effect against glutamate toxicity in a dose-dependent manner. Moreover, glutamate exposure dramatically raises intracellular calcium concentration in neurons, while quercetin attenuates this rise. Quercetin treatment also alleviates the glutamate-induced decline in parvalbumin expression. The hippocampus plays an important role in learning and memory. It is considered an area vulnerable to glutamate toxicity. HT22 cells have been accepted as an immortalized mouse hippocampal cell line widely used for studies of nerve damage or recovery. In particular, excitatory glutamate toxicity induces apoptosis in HT22 cells through the release of the mitochondrial apoptosis-inducing factor [31]. In this study, HT22 cells were used to investigate the effects of quercetin on glutamate toxicity in the hippocampus. We clearly showed that glutamate toxicity induces neuronal damage and quercetin has a protective effect on glutamate in HT22 cells.

Parvalbumin is a calcium-buffering protein that regulates the intracellular calcium concentration [32]. It is an important protein that constantly maintains the intracellular calcium concentration in nerve cells [33]. Overload of intracellular calcium concentration induces cell degradation and damage. An excessively high intracellular calcium level initiates the activation of protease and lipase, induces ROS generation and cell structure damage, and eventually leads to cell death [34]. In addition, excessive calcium influx increases mitochondrial permeability, releases cytochrome c from mitochondria to cytosol, and activates caspase cascade [35, 36]. Imbalance of intracellular calcium concentration causes various neurological disorders. Thus, it is accepted that the maintenance of intracellular calcium concentration is important for the survival of neurons [37]. We have previously shown that glutamate exposure reduces the expression of parvalbumin in neurons [38]. This study additionally showed that quercetin attenuates the glutamate-induced decrease in parvalbumin and preserves neurons against glutamate exposure. Quercetin restores nerve damage caused by glutamate toxicity and exerts protective effects. It also regulates intracellular calcium concentration and parvalbumin expression in glutamate-exposed neurons.

Quercetin attenuates neurobehavioral disorder and alleviates the reduction of parvalbumin expression in stroke animal models [27]. We additionally investigated whether quercetin prevents apoptotic cell death through parvalbumin regulation using an siRNA transfection manual. Our results demonstrated a decrease in parvalbumin expression and an increase in caspase-3 expression in siRNA-transfected cells. This finding demonstrated that parvalbumin regulates caspase-3 activation and contributes to apoptosis inhibition. Moreover, glutamate exposure induces increases in caspase-3 expression regardless of parvalbumin siRNA transfection, and these increases are higher in siRNA-transfected cells than in non-transfected cells. This study showed that quercetin alleviates an increase in caspase-3 in glutamate-exposed neurons. The alleviation effect of quercetin was more pronounced in non-transfected cells than in transfected cells. Caspase-3 is accepted as a representative protein that related to apoptosis. Bcl-2 family members are key regulators of cell death [39]. Bcl-2 is an inhibitor that prevents apoptosis and bax is an inducer that promotes apoptosis [40, 41]. Moreover, glutamate exposure causes the down-regulation of bcl-2 and the up-regulation of bax. The degree of change in bcl-2 and bax in the parvalbumin siRNA-transfected condition was higher than in the non-transfected condition. Quercetin prevents glutamate-induced changes regardless of siRNA transfection, but the effect of quercetin on bcl-2 and bax
regulation was weakened in parvalbumin siRNA-transfected cells. Our results also revealed a decrease in the ratio of bcl-2 to bax in glutamate-treated neurons. The ratio of bcl-2 to bax acts as a critical factor in determining cell death and cell survival. The decrease in the bcl-2 to bax ratio is more remarkable in siRNA-transfected neurons than in non-transfected neurons. Quercetin attenuates this decrease by glutamate exposure, and the recovery ability of quercetin on these protein changes was reduced in parvalbumin siRNA-transfected neurons. These results showed that parvalbumin contributes to bcl-2 and bax expression, and caspase-3 expression in glutamate-exposed neurons. Quercetin modulates both the down- and up-regulation of these proteins caused by glutamate toxicity. Our results indicate that quercetin regulates glutamate-induced apoptosis through the modulation of parvalbumin. We clearly elucidated the fact that quercetin modulates parvalbumin expression in glutamate-exposed cells, regulates intracellular calcium concentration, and results in the prevention of apoptosis by regulating bcl-2 family proteins and attenuating caspase-3 expression. In conclusion, these findings suggest that quercetin exerts a neuroprotective effect through the modulation of parvalbumin in glutamate-exposed neurons.

REFERENCES

1. Takeuchi A. The transmitter role of glutamate in nervous systems. Jpn J Physiol. 1987;37(4):559-572.
2. Lugon MD, Batsikadze G, Fresnoza S, Grundey J, Kuo MF, Paulus W, et al. Mechanisms of nicotinic modulation of glutamatergic neuroplasticity in humans. Cereb Cortex. 2017;27(1):544-553.
3. Peng S, Zhang Y, Zhang J, Wang H, Ren B. Glutamate receptors and signal transduction in learning and memory. Mol Biol Rep. 2011;38(1):453-460.
4. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799-817.
5. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett. 1985;58(3):293-297.
6. Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci U S A. 2004;101(20):7751-7756.
7. Gupta K, Hardingham GE, Chandran S. NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons. Neurosci Lett. 2013;543:95-100.
8. Hu NW, Ondrejcak T, Rowan MI. Glutamate receptors in preclinical research on Alzheimer’s disease: update on recent advances. Pharmacol Biochem Behav. 2012;100(4):855-862.
9. Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK, et al. Roles of glutamate receptors in Parkinson’s disease. Int J Mol Sci. 2019;20(18):4391.
10. Rueda CB, Llorente-Folch I, Traba J, Amigo I, Gonzalez-Sanchez P, Contreras L, et al. Glutamate excitotoxicity and Ca2+-regulation of respiration: Role of the Ca2+ activated mitochondrial transporters (CaMCs). Biochim Biophys Acta. 2016;1857(8):1158-1166.
11. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci. 1998;1(5):366-373.
12. Marambaud P, Dreesen-Werislinghoer U, Vingtdeux V. Calcium signaling in neurodegeneration. Mol Neurodegener. 2009;4(1):20.
13. Annunziato L, Amoroso S, Pannaccione A, Cataldi M, Pignataro G, D’Alessio A, et al. Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions. Toxicol Lett. 2003;139(2-3):125-133.

14. Heizmann CW. Parvalbumin, an intracellular calcium-binding protein; distribution, properties and possible roles in mammalian cells. Experientia. 1984;40(9):910-921.

15. Ruden JB, Dugan LL, Konradi C. Parvalbumin interneuron vulnerability and brain disorders. Neuropsychopharmacology. 2021;46(2):279-287.

16. Arif SH. A Ca(2+)-binding protein with numerous roles and uses: parvalbumin in molecular biology and physiology. BioEssays. 2009;31(4):410-421.

17. Schiavone S, Neri M, Trabace L, Turillazzi E. The NADPH oxidase NOX2 mediates loss of parvalbumin interneurons in traumatic brain injury: human autopic immunohistochemical evidence. Sci Rep. 2017;7(1):8752.

18. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983;32(7):1141-1148.

19. Chen S, Jiang H, Wu X, Fang J. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediators Inflamm. 2016;2016:9340637.

20. Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci. 2019;20(13):3177.

21. Wu XI, Zhou XB, Chen C, Mao W. Systematic investigation of quercetin for treating cardiovascular disease based on network pharmacology. Comb Chem High Throughput Screen. 2019;22(6):411-420.

22. Du G, Zhao Z, Chen Y, Li Z, Tian Y, Liu Z, et al. Quercetin protects rat cortical neurons against traumatic brain injury. Mol Med Rep. 2018;17(6):7859-7865.

23. Park DJ, Shah FA, Koh PO. Quercetin attenuates neuronal cells damage in a middle cerebral artery occlusion animal model. J Vet Med Sci. 2018;80(4):676-683.

24. Yang E, Kim GS, Kim JA, Song KS. Protective effects of onion-derived quercetin on glutamate-mediated hippocampal neuronal cell death. Pharmacogn Mag. 2013;9(36):302-308.

25. Sakanashi Y, Oyama K, Matsui H, Oyama TB, Oyama TM, Nishimura Y, et al. Possible use of quercetin, an antioxidant, for protection of cells suffering from overload of intracellular Ca2+: a model experiment. Life Sci. 2008;83(5-6):164-169.

26. Park DJ, Jeon SJ, Kang JB, Koh PO. Quercetin reduces ischemic brain injury by preventing ischemia-induced decreases in the neuronal calcium sensor protein hippocalcin. Neuroscience. 2020;430:47-62.

27. Park DJ, Kang JB, Shah FA, Koh PO. Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model. Lab Anim Res. 2021;37(1):9.

28. Oyama Y, Carpenter DO, Chikahisa L, Okazaki E. Flow-cytometric estimation on glutamate- and kainate-induced increases in intracellular Ca2+ of brain neurons: a technical aspect. Brain Res. 1996;728(1):121-124.

29. Kao JP, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem. 1989;264(14):8179-8184.

30. Maher P, Davis JB. The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci. 1996;16(20):6394-6401.

31. Fukui M, Song JH, Choi J, Choi HJ, Zhu BT. Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. Eur J Pharmacol. 2009;617(1-3):111.
32. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci. 1992;15(8):303-308.

33. Girard F, Meszar Z, Marti C, Davis FP, Celio M. Gene expression analysis in the parvalbumin-immunoreactive PV1 nucleus of the mouse lateral hypothalamus. Eur J Neurosci. 2011;34(12):1934-1943.

34. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium. 2010;47(2):122-129.

35. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86(1):147-157.

36. Smaili SS, Pereira GI, Costa MM, Rocha KK, Rodrigues L, do Carmo LG, et al. The role of calcium stores in apoptosis and autophagy. Curr Mol Med. 2013;13(2):252-265.

37. Berridge MJ. Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. Prion. 2013;7(1):2-13.

38. Koh PO. Ischemic injury decreases parvalbumin expression in a middle cerebral artery occlusion animal model and glutamate-exposed HT22 cells. Neurosci Lett. 2012;512(1):17-21.

39. Sanderson TH, Kumar R, Sullivan JM, Krause GS. Insulin blocks cytochrome c release in the reperfused brain through PI3-K signaling and by promoting Bax/Bcl-XL binding. J Neurochem. 2008;106(3):1248-1258.

40. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334-336.

41. Oltval ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74(4):609-619.